SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

BMN 820

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
If the Phase 3 ACTION 3 trial succeeds, a U.S. FDA submission could follow in 2028 or 2029, with potential approval in 2029-2030, assuming standard review timelines.
Why 3/10
BMN 820's next hard, dated catalyst is the Phase 3 ACTION 3 pivotal topline data readout, expected in 2028 (more than 12 months away). With no nearer-term binary catalyst and the drug representing a small part of BioMarin's diversified pipeline, the impact score is a 3 per the rubric for a mid-stage drug whose next catalyst is >12 months out.
Actionable Insight NEUTRAL

The next catalyst for BMN 820 is the Phase 3 ACTION 3 topline data readout, expected in 2028. Positive data would validate the FSGS opportunity for BioMarin's U.S. commercialization rights, while a miss would effectively zero out the program's value. In the nearer term, watch for any Dimerix disclosures on trial progress or interim analyses. BMN 820 is a small part of a large, diversified pipeline at BioMarin, so even a binary outcome would likely move BMRN shares by mid-single-digit percentages, not a make-or-break swing.

Price Chart

Loading chart...

Executive Summary

BMN 820 (repagermanium, formerly DMX-200) is a first-in-class oral CCR2 inhibitor in Phase 3 development for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with limited treatment options. BioMarin acquired exclusive U.S. commercialization rights through its acquisition of Amicus Therapeutics, which held the license from Australian developer Dimerix. The pivotal Phase 3 ACTION 3 trial (NCT05183646) is fully enrolled with 286 patients and passed a pre-specified interim efficacy analysis, maintaining >90% statistical power. Topline data are expected in 2028. The U.S. addressable patient population is roughly 30,000, but the drug faces a newly approved competitor in Travere's FILSPARI (sparsentan), approved for FSGS in April 2026. BMN 820 is one of several pipeline assets at BioMarin, a large-cap biotech with approved products (VOXZOGO, GALAFOLD) generating over $1 billion in quarterly revenue, so this single drug is not a make-or-break catalyst for the stock.

How It Works

BMN 820 (repagermanium) is an oral small-molecule drug that blocks the CCR2 receptor on immune cells. In focal segmental glomerulosclerosis (FSGS), a rare kidney disease where the kidney's filtering units become scarred, inflammatory signals attract immune cells via the CCR2 pathway, worsening the damage. By blocking CCR2, BMN 820 aims to reduce inflammation and scarring in the kidneys, slowing or halting disease progression. It is designed to be taken alongside a standard blood-pressure medication called an angiotensin II receptor blocker (ARB), and the two drugs work on related pathways that both contribute to kidney injury.

Trial Status

The pivotal Phase 3 ACTION 3 trial (NCT05183646) is fully enrolled with 286 patients across multiple global sites. The trial is a randomized, double-blind, placebo-controlled study evaluating DMX-200 120 mg twice daily versus placebo in FSGS patients on a stable ARB regimen. A pre-specified interim efficacy analysis in March 2024 was successful (non-futile), and an external blinded review confirmed >90% statistical power. The trial has a 104-week double-blind treatment period. Topline pivotal data are expected in 2028. Dimerix operates the trial; BioMarin holds exclusive U.S. commercialization rights.

The Two-Sided Case

▲ Bull Case5
BMN 820 is a first-in-class oral CCR2 inhibitor addressing a high-unmet-need rare kidney disease with a U.S. addressable patient population of approximately 30,000.
The Phase 3 ACTION 3 trial is fully enrolled (286 patients) and passed a pre-specified interim efficacy analysis in March 2024, with an external blinded review confirming >90% statistical power.
BioMarin acquired the U.S. rights through its Amicus Therapeutics acquisition, adding a late-stage asset to its rare-disease portfolio without upfront clinical risk.
The drug targets a broad FSGS population regardless of nephrotic syndrome status, potentially differentiating it from FILSPARI, which is approved only for patients without nephrotic syndrome.
Analyst consensus on BMRN is bullish (27 Buy/Strong Buy vs 8 Hold, mean price target $91.56, implying ~57% upside from the recent close).
▼ Bear Case5
The Phase 3 ACTION 3 trial is run by Dimerix, not BioMarin, and BioMarin only holds U.S. commercialization rights, limiting upside capture. Dimerix operates the trial and controls the data timeline.
Travere Therapeutics' FILSPARI (sparsentan) was approved by the FDA for FSGS in April 2026, establishing a first-in-class approved competitor that could limit BMN 820's market opportunity.
FSGS is a heterogeneous disease with a history of clinical trial failures, making Phase 3 success uncertain despite positive Phase 2 data.
Pivotal data is not expected until 2028, more than 12 months away, with no nearer-term binary catalysts for this specific asset.
BioMarin's stock has been under pressure (post-market at $54.50, down ~5% after Q3 earnings) and the company lowered full-year 2026 guidance, reflecting broader execution risk.

Upcoming Catalysts

  • Phase 3 ACTION 3 pivotal topline data readout (expected 2028)
  • Any Dimerix disclosures on interim analyses or trial progress updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 11

Hover a chip for the title
1 biomarin.com2 investors.biomarin.com3 prnewswire.com4 investors.dimerix.com5 novapharmanews.com6 portraitresearch.com7 sciencedirect.com8 expertmarketresearch.com9 sec.gov10 dimerix.com11 clinicaltrials.gov